BDX — BECTON DICKINSON & CO

NYSE · Health Care · Health Care Equipment & Supplies · CIK 10795 ·
Last close
$143.92
Market Cap
$39.66B
52W High
$159.07
52W Low
$140.11
ADV30
2,783,910
Next earnings
2026-08-06
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 4,714,000,000 2,154,000,000 626,000,000 -311,000,000 50,832,000,000 813,000,000 26,700,000,000
Dec 2025 5,252,000,000 2,411,000,000 662,000,000 382,000,000 54,841,000,000 740,000,000 29,559,000,000
Sep 2025 5,891,000,000 2,799,000,000 826,000,000 493,000,000 55,325,000,000 641,000,000 29,935,000,000
Jun 2025 5,509,000,000 2,634,000,000 979,000,000 574,000,000 54,902,000,000 735,000,000 29,429,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$3,394,000,000
Investing CF
$-1,205,000,000
Financing CF
$-1,990,000,000
CapEx
$-763,000,000
Dividends Paid
$-1,193,000,000
Buybacks
$-1,000,000,000
EPS Diluted TTM
$5.45
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$16,704,000,000
Inventory
$4,085,000,000
Receivables
$2,508,000,000
ST Investments
$11,000,000
EBIT TTM
$2,580,000,000
Pretax Income TTM
$1,969,000,000
Interest Exp TTM
$611,000,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$22,226,999,296
EBITDA
$6,157,000,192
Free Cash Flow
$4,531,250,176
Enterprise Value
$56,118,779,904
Total Cash
$816,000,000
Total Debt
$17,279,000,576
Shares Out
275,540,427
Trailing EPS
$5.73
Book Value
$87.58
ROE
6.7%
ROA
4.4%
Div Yield
2.92%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Sep 2025 21,840,000,000 2,986,000,000 1,678,000,000 55,325,000,000 29,935,000,000 3,431,000,000
Sep 2024 20,178,000,000 2,856,000,000 1,705,000,000 57,286,000,000 31,397,000,000 3,797,000,000
Sep 2023 19,372,000,000 2,424,000,000 1,484,000,000 52,780,000,000 26,983,000,000 2,989,000,000
Sep 2022 18,870,000,000 2,475,000,000 1,779,000,000 52,934,000,000 27,652,000,000 2,633,000,000

TTM Snapshot

Revenues TTM
$19,677,000,000
NetIncome TTM
$1,557,000,000
OpCashFlow TTM
$0
Assets (Latest)
$55,325,000,000
Forward EPS
$13.39

Max Pain — expiry 2026-07-17

max pain strike: $145.00 · spot: $147.77 · call oi: 2,745 · put oi: 2,279
Expected Move to 2026-07-17: ±$8.55 (5.79%) — implied range $139.22$156.32 · ATM straddle on $150.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EW Edwards Lifesciences Corp $50.07B $86.95
FSNUF Fresenius SE & Co. KGaA $30.61B $54.35
MDLN Medline Inc. $29.85B $35.30
GEHC GE HealthCare Technologies Inc. $28.99B $63.72
RMD RESMED INC $27.74B $191.26

News headlines (Yahoo Finance, 1h cache)

How Are Emerging Markets Supporting Abbott's EPD Momentum?
2026-06-24 12:52 · Yahoo
BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
2026-06-23 10:50 · Yahoo
Becton Dickinson (BDX) Issues Voluntary Recall for Select Skin Preparation Products
2026-06-23 08:35 · Yahoo
How to Approach Abbott Stock Following Its Sharp YTD Decline?
2026-06-22 13:10 · Yahoo
3 Excellent Dividend Stocks to Buy on the Dip
2026-06-22 06:05 · Yahoo
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?
2026-06-21 11:09 · Yahoo
Global Closed System Drug Transfer Devices Market Size/Share Worth USD 3.21 Billion by 2035 at a 8.3% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, G
2026-06-18 17:30 · Yahoo
Here's Why You Should Retain BDX Stock in Your Portfolio Now
2026-06-16 13:54 · Yahoo
BofA Trims Becton Dickinson (BDX) Target as Medtech Headwinds Persist
2026-06-15 19:24 · Yahoo
Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now?
2026-06-12 18:17 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.